medigraphic.com
ISSN 0188-9796 (Impreso)

2007, Número 1

<< Anterior Siguiente >>

Rev Endocrinol Nutr 2007; 15 (1)


La próstata como riesgo principal en la aplicación de un tratamiento hormonal sustitutivo

Lamm WL, Porias CH

Idioma: Español
Referencias bibliográficas: 43
Paginas: 19-23
Archivo PDF: 124.83 Kb.


RESUMEN

Desde el inicio de los años cuarenta se demostró la dependencia hormonal que tiene el cáncer de próstata con la testosterona (T). Se sabe perfectamente que la administración de T en un cáncer de próstata favorecerá su progresión. Por otro lado, curiosamente las personas castradas en una edad joven no desarrollan hiperplasia prostática ni cáncer de próstata, y por el contrario, la glándula prostática sufre una involución. Sin embargo, a medida que se ha incrementado la expectativa de vida en el hombre, ha surgido la posibilidad de tratamientos hormonales sustitutivos que mejoren su calidad de vida, y también la necesidad de un mejor entendimiento en la relación existente entre los andrógenos y el tejido prostático, así como sus riesgos y beneficios. Hoy día se ha demostrado que los cambios tanto benignos como malignos que pueda presentar el tejido prostático también están influenciados por la presencia de diversas hormonas, enzimas, factores de crecimiento y códigos genéticos, y que además requieren de la influencia androgénica para poder ejercer sus efectos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Claus GR et al. Campbell’s Urology 8th edition. Chapter 38. Etiology, Pathophisiology, Prevalence & Natural History of Benign Prostatic hyperplasia. pp 2-15.

  2. Huggins C, Hodges CV. Studies on prostate cancer. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.

  3. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing hormone-releasing hormone agonist on benign prostatic hyperplasia. N Eng J Med 1987; 317: 599-604.

  4. McConnell JD, Barry MJ, Bruskewitz RC et al. Benign prostatic hyperplasia: diagnosis & treatment. Clinical Practice Guideline, Number 8. Rockville, Md, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1994.

  5. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during progression of therapy for prostate cancer. Prostate 1996; 28: 251-265.

  6. Newling D. Antiandrogens in the treatment of prostate cancer. B J Urol 1996; 77: 776-784

  7. Isaacs J, Coffey D. Androgenic control of prostatic growth, regulation of steroid levels. Prostate Cancer. Geneva. UICC. 1979; 48: 112-122.

  8. Andriole G, Bruchovsky N. DHT & the Prostate: The scientific rationale for 5-alfa-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004; 172: 1399-1403.

  9. Neaves WB, Johnson L. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in the aging male. J Clin Endocrinol Metab 1984; 55: 756-63.

  10. Hargreave TB, Meuleman EJH. Hormonal replacement therapy for the aging male? The debate goes on. European Urology 2004; 46: 155-161.

  11. Habenicht UF, El Etreby MF. The periuretral zone of the prostate of the cynomologus monkey is the most sensitive part for estrogenic stimulus. Prostate 1988; 13: 305-316.

  12. Neubauer B, Bisser T. Antagonism of androgen and estrogen effects in the guinea pig seminal vesicle, epithelium and fibromuscular stroma. Prostate 1989; 15: 273-286.

  13. Kreewer A, Nedville R. The effects of estrogen and prolactin production on the benign prostatic hyperplasia. European Urology 2002; 42: 123-127.

  14. Silver RI, Wiley EL. Cell type specific expression of steroid 5 alfa-reductase II. J Urol 1994b; 152: 438-442.

  15. Andriole G, Bruchovsky N. DHT & the Prostate: The scientific rationale for 5-alfa-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004; 172: 1399-1403.

  16. Andriole G, Bruchovsky N. DHT and the Prostate: The scientific rationale for 5-alfa-reductase inhibitors in the treatment of benign prostatic hyperplasia. Eur Urol 2003; 44: 82.

  17. Janda E, Litos G, Grunert S, Downward J, Beug H. Oncogenic Ras/Her-2 mediate hyperproliferation of polarized epithelial cellsin 3D culturesand rapid tumor growth via the PI3K pathway. Oncogene 2002; 21: 5148.

  18. Boyer B, Valles AM, Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 2000; 60: 1091.

  19. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003; 112: 1486.

  20. Tchernof A, Despres JP. Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm Metab Res 2000; 32: 526.

  21. Haffner SM. Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: epidemiological and clinical correlation. Int J Obes Relat Metab Disord 2000; suppl. 24: S56.

  22. Dahle SE, Anand P. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168: 599-604.

  23. Chokkalingam AP, Gao Y-T, Deng J, Stanczyk FZ, Sesterhenn IA, Mostofi FK et al. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 2002; 52: 98.

  24. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39: 151.

  25. Ellis L, Nyborg H. Racial/ethnic variations in male testosterone levels: a probable contributor to group differences in health. Steroids 1992; 57: 72.

  26. Kubricht WS, 3rd, Williams BJ, Whatley T, Pinckard P, Eastham JA. Serum testosterone levels in African-American and white men undergoing prostate biopsy. Urology 1999; 54: 1035.

  27. Mohler JL, Gaston KE. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol 2004; 171: 2277-2280.

  28. Hoffmann M, De Wolf W, Morgenthaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000; 163: 824-827.

  29. Schatzl G, Madersbacher S. High grade prostate cancer is associated with low serum testosterone levels. The Prostate 2001; 47: 52-58.

  30. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215.

  31. Fowler JE Jr, Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981; 126: 372-375.

  32. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in a community based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860-864.

  33. Fang J, Metter EJ, Landis P, Carter HB. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/mL. Urology 2002; 59: 889-894.

  34. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994; 8: 439-443.

  35. Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, Haitel A, Marberger M. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001; 47: 52-58.

  36. Svetec DA, Canby ED, Thompson IM, Sabanegh ES Jr. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol 1997; 158: 1775-1777.

  37. Tenover JS. Testosterone for all? The 80th Endocrine Society Meetings. New Orleans, Louisiana, June 24-27, 1998; abstract S-8-1.

  38. 2002 IMS sales data, Philadelphia, Pa; BMC Corporation sales data, Minneapolis, Minn.

  39. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000; 163: 824.

  40. Morales A. Andropause (or symptomatic late onset hypogonadism): Facts, Fiction and Controversies. Aging Male 2003; 7: 297-303.

  41. Schatzl G, BroÈssner C, Schmid S, Kugler W, Roehrich M, Treu T, Szalay A, Djavan B, Schmidbauer CP, SoÈregi S, Madersbacher S. Prostate Study Group of the Austrian Society of Urology. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and LUTS function. Urology 2000; 55: 397-402.

  42. Piyush K. Agarwal. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005; 173: 533-536.

  43. Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl 2001; 22: 718.




2020     |     www.medigraphic.com